GCS
COGT icon

Gordian Capital (Singapore)’s Cogent Biosciences COGT Stock Holding History

Gordian Capital (Singapore)’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-2,700
Closed -$104K – 133
2026
Q1 		$104K Sell
2,700
-1,800
-40% -$66.5K 0.17% 78
2025
Q4 		$160K Sell
4,500
-4,500
-50% -$127K 0.22% 68
2025
Q3 		$129K Buy
9,000
+5,800
+181% +$68.7K 0.17% 77
2025
Q2 		$23K Buy
+3,200
New +$17.7K 0.03% 101

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Gordian Capital (Singapore)'s COGT Position: Q2 2026 in Review

Gordian Capital (Singapore) sold out of Cogent Biosciences (COGT) in Q2 2026, closing a stake of 2,700 shares — an estimated $104K sold.

Gordian Capital (Singapore) first reported a position in COGT in Q2 2025 and held it in 4 quarters. The position peaked at $160K in Q4 2025. 323 funds tracked by Wall St. Rank hold COGT as of Q2 2026.

  • Gordian Capital (Singapore) reported no remaining Cogent Biosciences position as of Q2 2026 after selling out during the quarter.
  • Gordian Capital (Singapore) sold 2,700 Cogent Biosciences shares in Q2 2026, an estimated $104K.
  • Gordian Capital (Singapore) first reported a position in Cogent Biosciences in Q2 2025 and held it in 4 quarters.
  • Gordian Capital (Singapore)'s Cogent Biosciences position peaked at $160K in Q4 2025.
  • 323 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2026.

Based on Gordian Capital (Singapore)'s 13F filing for Q2 2026, filed 13 Aug 2026.